285 related articles for article (PubMed ID: 24245445)
1. [Orphan drugs].
Golocorbin Kon S; Vojinović A; Lalić-Popović M; Pavlović N; Mikov M
Med Pregl; 2013; 66(9-10):373-8. PubMed ID: 24245445
[TBL] [Abstract][Full Text] [Related]
2. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
3. Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
Sarpatwari A; Beall RF; Abdurrob A; He M; Kesselheim AS
Health Aff (Millwood); 2018 May; 37(5):732-737. PubMed ID: 29733729
[TBL] [Abstract][Full Text] [Related]
4. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
Daniel MG; Pawlik TM; Fader AN; Esnaola NF; Makary MA
Am J Clin Oncol; 2016 Apr; 39(2):210-3. PubMed ID: 26580246
[TBL] [Abstract][Full Text] [Related]
5. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
6. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
7. The impact of the Orphan Drug Act on Food and Drug Administration-approved therapies for rare skin diseases and skin-related cancers.
Karas L; Lu CY; Agrawal PB; Asgari MM
J Am Acad Dermatol; 2019 Sep; 81(3):867-877. PubMed ID: 31103566
[TBL] [Abstract][Full Text] [Related]
8. Developing treatments for inborn errors: incentives available to the clinician.
Haffner ME
Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976
[TBL] [Abstract][Full Text] [Related]
9. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
Pariser AR; Xu K; Milto J; Coté TR
Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
[TBL] [Abstract][Full Text] [Related]
10. Orphan Drugs in Oncology.
Korchagina D; Jaroslawski S; Jadot G; Toumi M
Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
[TBL] [Abstract][Full Text] [Related]
11. Drugs for rare disorders.
Cremers S; Aronson JK
Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
[TBL] [Abstract][Full Text] [Related]
12. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
13. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
14. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
Wellman-Labadie O; Zhou Y
Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
[TBL] [Abstract][Full Text] [Related]
15. Do investors value the FDA orphan drug designation?
Miller KL
Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
[TBL] [Abstract][Full Text] [Related]
16. [Orphan drugs : New opportunities for the treatment of rare diseases].
Beck M
Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
[TBL] [Abstract][Full Text] [Related]
17. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
Kumar Kakkar A; Dahiya N
Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
[TBL] [Abstract][Full Text] [Related]
18. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
19. Adopting an orphan.
Rinaldi A
EMBO Rep; 2005 Jun; 6(6):507-10. PubMed ID: 15940282
[TBL] [Abstract][Full Text] [Related]
20. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
